

APPLICANT FACSIMILE OF FORM PTO-1449

REV 7-80

U.S. DEPARTMENT OF
COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

SERIAL NO.

WII-014CP

09/965131

APPLICANT

CHUNG, Maureen A. *et al.*

FILING DATE

September 26, 2001

GROUP

1632

LIST OF PUBLICATIONS CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
WJ	A1	5,591,632	01/97	O'Donnell <i>et al.</i>	435	252.3	
	A2	5,776,465	07/98	O'Donnell <i>et al.</i>	424	200.1	
	A3	6,270,776 B1	08/01	Bloom <i>et al.</i>	424	248.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

WJ	A4	✓	Acres, B. <i>et al.</i> , "MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines," <i>Cancer Immunol. Immunother.</i> 2000 Jan;48(10):588-94.
	A5	✓	Aldovini, A <i>et al.</i> "Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines," <i>Nature</i> . 1991 Jun 6;351(6326):479-82.
	A6	✓	Apostolopoulos, V. <i>et al.</i> , "Cellular mucins: targets for immunotherapy," <i>Critical Reviews in Immunology</i> 1994;14(3&4):293-309.
	A7	✓	Bornstein, R.S. <i>et al.</i> , "Immunotherapy of melanoma with intralesional BCG," <i>Natl. Cancer Inst. Monogr.</i> 1973 Dec;39:213-20.
	A8	✓	Bu, D. <i>et al.</i> , "Recombinant vaccinia mucin vector: in vitro analysis of expression of tumor-associated epitopes for antibody and human cytotoxic T-cell recognition," <i>Journal of Immunother.</i> 1993 Aug;14(2):127-35.
	A9	✓	Ciborowski, P. <i>et al.</i> , "Recombinant epithelial cell mucin (MUC-1) expressed in baculovirus resembles antigenically tumor associated mucin, target for cancer immunotherapy," <i>Biomedical Peptides, Proteins & Nucleic Acids</i> . 1995;1(3):193-8.
	A10	✓	Croce, M.V. <i>et al.</i> , "Expression of tumour associated antigens in normal, benign and malignant human mammary epithelial tissue: a comparative immunohistochemical study," <i>Anticancer Research</i> . 1997 Nov-Dec;17(6D):4287-92.
	A11	✓	Davies, M., "Bacterial cells as anti-tumour agents in man," <i>Reviews on Environmental Health</i> . 1982; 4(1):31-56.
	A12	✓	Duda, R.B. <i>et al.</i> "Recombinant BCG therapy suppresses melanoma tumor growth," <i>Annals of Surgical Oncology</i> . 1995 Nov;2(6):542-9.
	A13	✓	Emoto, M. <i>et al.</i> , "Induction of IFN- γ -producing CD4 ⁺ natural killer T cells by <i>Mycobacterium bovis</i> bacillus Calmette Guérin," <i>Eur. J. Immunol.</i> 1999 Feb;29(2):650-9.
	A14	✓	Fricker, J. "Mucin-based vaccines and cancer," <i>Molecular Medicine Today</i> . 1997 Feb;3(2):47.
	A15	✓	Gilewski, T. <i>et al.</i> , "Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21," <i>Clinical Cancer Research</i> . 2000 May;6(5):1693-701.
	A16	✓	Girling, A. <i>et al.</i> , "A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas," <i>Int. J. Cancer</i> . 1989 Jun 15;43(6):1072-6.


Examiner

Date Considered

3/22/03

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED
SEP 3 2002
TECH CENTER 1600 2900

REV 7-80

WII-014CP

09/96513

APPLICANT

CHUNG, Maureen A. et al.

FILING DATE

September 26, 2001

GROUP

1632

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO


OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

B1	✓	Goydos, J.S. et al., "A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma," <i>Journal of Surgical Research</i> . 1996 Jun;63(1):298-304.
B2	✓	Henderson, R.A. et al., "Retroviral expression of MUC-1 human tumor antigen with intact repeat structure and capacity to elicit immunity in vivo," <i>Journal of Immunotherapy</i> . 1998 Jul;21(4):247-56.
B3	✓	Hilkens, J. et al., "Is episialin/MUC1 involved in breast cancer progression?" <i>Cancer Letters</i> 1995 Mar 23;90(1):27-33.
B4	✓	Irimura, T. et al., "Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity," <i>J. Biochem. (Tokyo)</i> , 1999 Dec;126(6):975-85.
B5	✓	Jerome, K.R. et al., "Expression of tumor-associated epitopes on Epstein-Barr virus-immortalized B-cells and Burkitt's lymphomas transfected with epithelial mucin complementary DNA," <i>Cancer Research</i> . 1992 Nov 1;52(21):5985-90.
B6	✓	Karanikas, V. et al., "Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein," <i>J. Clin. Invest.</i> 1997 Dec 1;100(11):2783-92.
B7	✓	Koido, S. et al., "Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA," <i>Journal of Immunology</i> . 2000 Nov 15;165(10):5713-9.
B8	✓	Kotera, Y. et al., "Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients," <i>Cancer Research</i> . 1994 Jun 1;54(11):2856-60.
B9	✓	Morton, D.L. et al., "Vaccine therapy for malignant melanoma," <i>Ca. Cancer J. Clin.</i> 1996 Jul-Aug;46(4):225-44.
B10	✓	O'Donnell, M.A. et al., "Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer: new prospects for an old warhorse," <i>Surg. Oncol. Clin. N. Am.</i> 1995; 4(2):189-201.
B11	✓	Patard, J.J. et al., "Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer," <i>World J. Urol.</i> 1993;11(3):165-8.
B12	✓	Penichet, M.L. et al., "Antibody-IL-2 fusion proteins: a novel strategy for immune potentiation," <i>Hum. Antibodies</i> . 1997;8(3):106-18.
B13	✓	Pietersz, G.A. et al., "Parameters for using mannan-MUC1 fusion protein to induce cellular immunity," <i>Cancer Immunol Immunother.</i> 1998 Feb;45(6):321-6.
B14	✓	Poppas, D.P. et al., "Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10," <i>Urology</i> . 1998 Aug;52(2):268-75; discussion 275-6.


Date Considered

3/22/03

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED
SEP 03 2002
TECH CENTER 1600/2900



APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO WII-014CP	SHEET NO. 09/965131
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT CHUNG, Maur en A. et al.	GROUP 1632
		FILING DATE September 26, 2001	

Sheet 3
RECEIVED
SEP 03 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

C1	✓	Rosenberg, S.A., "Identification of cancer antigens: impact on development of cancer immunotherapies," <i>The Cancer Journal</i> . 6(Supp 3):S200-207.
C2	✓	Rowse, G.J. et al., "Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model," <i>Cancer Research</i> 1998 Jan 15;58(2):315-21.
C3	✓	Schlom, J. et al., "Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer," <i>Breast Cancer Research and Treatment</i> . 1996;38(1):27-39.
C4	✓	Scholl, S.M. et al., "Vaccination contre les cellules tumorales mammaires exprimant la mucine MUC1," <i>Bull. Cancer</i> . 1997 Jan;84(1):61-4. French with English abstract.
C5	✓	Scholl, S.M. et al., "Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer," <i>J. Immunother</i> . 2000 Sep-Oct;23(5):570-80.
C6	✓	Siddiqui, J. et al., "Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 1988 Apr;85(7):2320-3.
C7	✓	Stover, C.K. et al., "New use of BCG for recombinant vaccines.," <i>Nature</i> , 1991 Jun 6;351(6326):456-60.
C8	✓	Taylor-Papadimitriou, J. et al., "MUC1 and cancer," <i>Biochimica et Biophysica Acta</i> . 1999 Oct 8;1455(2-3):301-13.
C9	✓	von Mensdorff-Pouilly, S. et al., "Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin," <i>Journal of Clinical Oncology</i> . 2000 Feb;18(3):574-83.
C10	✓	Walsh, M.D. et al., "Heterogeneity of MUC1 expression by human breast carcinoma cell lines <i>in vivo</i> and <i>in vitro</i> ," <i>Breast Cancer Research and Treatment</i> . 2000;58(3):255-66.
Examiner <i>[Signature]</i>	Date Considered <i>3/22/03</i>	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		